Table 1 The distribution of clinical and pathological characteristics in BC patients (n(%)).
Clinical pathogenic parameters | n | Nonmetastasis | Metastasis | \(\chi^{2}\) | P |
|---|---|---|---|---|---|
Age | |||||
0~ | 91 | 43 (44.33) | 48 (49.48) | 0.517 | 0.472 |
50~ | 103 | 54 (55.67) | 49 (50.52) | ||
ER | |||||
− | 75 | 31 (31.96) | 44 (45.36) | 3.674 | 0.055 |
+ | 119 | 66 (68.04) | 53 (54.64) | ||
PR | |||||
− | 102 | 44 (45.36) | 58 (59.79) | 4.052 | 0.044 |
+ | 92 | 53 (54.64) | 39 (40.21) | ||
HER2 | |||||
−/+ | 123 | 63 (64.95) | 60 (61.86) | 0.200 | 0.655 |
+++ | 71 | 34 (35.05) | 37 (38.14) | ||
E-Cad | |||||
− | 22 | 13 (13.40) | 9 (10.23) | 0.820 | 0.365 |
+ | 172 | 84 (85.60) | 88 (89.77) | ||
P53 | |||||
− | 100 | 53 (54.64) | 47 (48.45) | 0.743 | 0.389 |
+ | 94 | 44 (45.36) | 50 (51.55) | ||
Ki67 | |||||
0~ | 50 | 28 (28.87) | 22 (22.68) | 0.970 | 0.325 |
20~ | 144 | 69 (71.13) | 75 (77.32) | ||
Molecular | |||||
Luminal A | 34 | 21 (21.65) | 13 (13.40) | 4.386 | 0.356 |
Luminal B | 51 | 26 (26.80) | 25 (25.77) | ||
Luminal HER2 | 43 | 23 (23.71) | 20 (20.62) | ||
HER2-enriched | 23 | 10 (10.31) | 13 (13.40) | ||
Basal-like | 43 | 17 (17.53) | 26 (26.80) | ||
Number of lymph node metastases | |||||
0 | 65 | 45 (46.39) | 20 (20.62) | 24.806 | < 0.001 |
1~ | 41 | 25 (25.77) | 16 (16.49) | ||
4~ | 37 | 12 (12.37) | 25 (25.77) | ||
10~ | 51 | 15 (15.46) | 36 (37.11) | ||
Tissue pathology | |||||
In situ cancer | 11 | 7 (7.22) | 4 (4.12) | 0.867 | 0.352 |
Infiltrated nonspecific BC | 183 | 90 (92.78) | 93 (95.88) | ||
Size of the lump (cm) | |||||
0~ | 52 | 29 (29.90) | 23 (23.71) | 2.170 | 0.338 |
2~ | 116 | 53 (54.64) | 63 (64.95) | ||
5~ | 26 | 15 (15.46) | 11 (11.34) | ||
WHO level | |||||
I | 6 | 5 (5.15) | 1 (1.03) | 3.206 | 0.201 |
II | 121 | 57 (58.76) | 64 (65.98) | ||
III | 67 | 35 (36.08) | 32 (32.99) | ||
